These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27076760)

  • 61. Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody.
    Lee FT; Hall C; Rigopoulos A; Zweit J; Pathmaraj K; O'Keefe GJ; Smyth FE; Welt S; Old LJ; Scott AM
    J Nucl Med; 2001 May; 42(5):764-9. PubMed ID: 11337573
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Smart IR780 Theranostic Nanocarrier for Tumor-Specific Therapy: Hyperthermia-Mediated Bubble-Generating and Folate-Targeted Liposomes.
    Guo F; Yu M; Wang J; Tan F; Li N
    ACS Appl Mater Interfaces; 2015 Sep; 7(37):20556-67. PubMed ID: 26322900
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model.
    Noorani L; Stenzel M; Liang R; Pourgholami MH; Morris DL
    J Nanobiotechnology; 2015 Mar; 13():25. PubMed ID: 25890381
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
    Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
    Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
    Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
    Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Human sodium iodide symporter added to multidrug resistance 1 small hairpin RNA in a single gene construct enhances the therapeutic effects of radioiodine in a nude mouse model of multidrug resistant colon cancer.
    Jeon YH; Ahn SJ; Lee YJ; Lee YL; Lee SW; Park SY; Kim IS; Ahn BC; Ha JH; Lee J
    Cancer Biother Radiopharm; 2010 Dec; 25(6):671-9. PubMed ID: 21204761
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
    Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
    Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
    [TBL] [Abstract][Full Text] [Related]  

  • 71. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
    Yoon J; Koo KH; Choi KY
    Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
    J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy.
    Kim EJ; Kim BS; Choi DB; Chi SG; Choi TH
    Oncol Rep; 2016 Jun; 35(6):3159-68. PubMed ID: 27035553
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
    Gong JH; Liu XJ; Li Y; Zhen YS
    Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Development of a Potential Gallium-68-Labelled Radiotracer Based on DOTA-Curcumin for Colon-Rectal Carcinoma: From Synthesis to In Vivo Studies.
    Orteca G; Pisaneschi F; Rubagotti S; Liu TW; Biagiotti G; Piwnica-Worms D; Iori M; Capponi PC; Ferrari E; Asti M
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759785
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
    Sui H; Shi C; Yan Z; Li H
    Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
    [TBL] [Abstract][Full Text] [Related]  

  • 77. SPECT imaging evaluation of
    Shih BB; Chang YF; Cheng CC; Yang HJ; Chang KW; Ho AS; Lin HC; Yeh C; Chang CC
    J Chin Med Assoc; 2017 Dec; 80(12):766-773. PubMed ID: 28969991
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer.
    Goetz M; Hoetker MS; Diken M; Galle PR; Kiesslich R
    Endoscopy; 2013 Jun; 45(6):469-77. PubMed ID: 23580409
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
    Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
    Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models.
    Miyamoto Y; Muguruma N; Fujimoto S; Okada Y; Kida Y; Nakamura F; Tanaka K; Nakagawa T; Kitamura S; Okamoto K; Miyamoto H; Sato Y; Takayama T
    Cancer Sci; 2019 Jun; 110(6):1921-1930. PubMed ID: 30973663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.